BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26614010)

  • 1. Degree of nephrotoxicity after intermediate- or high-dose cisplatin-based chemoradiotherapy in patients with locally advanced head and neck cancer.
    Driessen CM; Uijen MJ; van der Graaf WT; van Opstal CC; Kaanders JH; Nijenhuis T; van Herpen CM
    Head Neck; 2016 Apr; 38 Suppl 1():E1575-81. PubMed ID: 26614010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
    van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW
    BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin.
    Patimarattananan T; Nongnuch A; Pattaranutaporn P; Unwanatham N; Jiarpinitnun C; Ngamphaiboon N
    Support Care Cancer; 2021 Feb; 29(2):877-887. PubMed ID: 32524284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.
    Driessen CM; de Boer JP; Gelderblom H; Rasch CR; de Jong MA; Verbist BM; Melchers WJ; Tesselaar ME; van der Graaf WT; Kaanders JH; van Herpen CM
    Eur J Cancer; 2016 Jan; 52():77-84. PubMed ID: 26655558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy.
    Faig J; Haughton M; Taylor RC; D'Agostino RB; Whelen MJ; Porosnicu Rodriguez KA; Bonomi M; Murea M; Porosnicu M
    Am J Clin Oncol; 2018 May; 41(5):432-440. PubMed ID: 27281266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-dependent hemato- and nephrotoxicity in patients with head and neck cancer receiving chemoradiotherapy with weekly cisplatin.
    Weykamp F; Seidensaal K; Rieken S; Green K; Mende S; Zaoui K; Freier K; Adeberg S; Debus J; Welte SE
    Strahlenther Onkol; 2020 Jun; 196(6):515-521. PubMed ID: 31784802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer.
    Falchook AD; Green R; Knowles ME; Amdur RJ; Mendenhall W; Hayes DN; Grilley-Olson JE; Weiss J; Reeve BB; Mitchell SA; Basch EM; Chera BS
    JAMA Otolaryngol Head Neck Surg; 2016 Jun; 142(6):517-23. PubMed ID: 27149571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Observance and results of concurrent chemoradiotherapy after induction chemotherapy by docetaxel, cisplatin and 5-fluoro-uracil for locally advanced head and neck cancers].
    Calderon B; Guerder C; Resbeut M; Fakhry N; Dupuis C; Cowen D
    Cancer Radiother; 2016 Apr; 20(2):83-90. PubMed ID: 26969244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: a multicenter analysis in Thailand.
    Ngamphaiboon N; Dechaphunkul A; Setakornnukul J; Dechaphunkul T; Jiratrachu R; Suktitipat B; Jiarpinitnun C; Pattaranutaporn P; Danchaivijitr P
    BMC Cancer; 2020 Jun; 20(1):518. PubMed ID: 32493288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity and efficacy of accelerated radiotherapy with concurrent weekly cisplatin for locally advanced head and neck carcinoma.
    Driessen CM; Janssens GO; van der Graaf WT; Takes RP; Merkx TA; Melchers WJ; Kaanders HA; van Herpen CM
    Head Neck; 2016 Apr; 38 Suppl 1():E559-65. PubMed ID: 25810154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome and morbidity after treatment with accelerated radiotherapy and weekly cisplatin for locally advanced head-and-neck cancer: results of a multidisciplinary late morbidity clinic.
    Rütten H; Pop LA; Janssens GO; Takes RP; Knuijt S; Rooijakkers AF; van den Berg M; Merkx MA; van Herpen CM; Kaanders JH
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):923-9. PubMed ID: 21095074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: which dose is more suitable?
    Ilhan Y; Onder AH; Ozbay MF; Karakaya G; Sezgin Goksu S; Ozturk B; Coskun HS
    Eur Rev Med Pharmacol Sci; 2024 May; 28(9):3403-3413. PubMed ID: 38766796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma.
    Liu YJ; Zhu GP; Guan XY
    Oral Oncol; 2012 Jun; 48(6):554-9. PubMed ID: 22289637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
    McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
    Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse drug reactions and kinetics of cisplatin excretion in urine of patients undergoing cisplatin chemotherapy and radiotherapy for head and neck cancer: a prospective study.
    Visacri MB; Pincinato EC; Ferrari GB; Quintanilha JCF; Mazzola PG; Lima CSP; Moriel P
    Daru; 2017 Apr; 25(1):12. PubMed ID: 28438219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
    Ishitsuka R; Miyazaki J; Ichioka D; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Kawai K; Nishiyama H
    Clin Exp Nephrol; 2017 Aug; 21(4):732-740. PubMed ID: 27565169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
    Giralt J; Trigo J; Nuyts S; Ozsahin M; Skladowski K; Hatoum G; Daisne JF; Yunes Ancona AC; Cmelak A; Mesía R; Zhang A; Oliner KS; VanderWalde A
    Lancet Oncol; 2015 Feb; 16(2):221-32. PubMed ID: 25596659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience.
    Cavalieri S; Platini F; Barretta F; Nuzzolese I; Ottini A; Bergamini C; Resteghini C; Colombo E; Iacovelli NA; Franceschini M; Calareso G; Di Pede P; De Feo G; Gandelli M; Toffolatti L; Guglielmo M; Ripamonti CI; Cosmai L; Licitra L; Alfieri S
    Oral Oncol; 2023 Nov; 146():106579. PubMed ID: 37778228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hearing and tinnitus in head and neck cancer patients after chemoradiotherapy.
    Niemensivu R; Saarilahti K; Ylikoski J; Aarnisalo A; Mäkitie AA
    Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2509-14. PubMed ID: 26685859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
    Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
    Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.